119 related articles for article (PubMed ID: 12885802)
1. Prognostic significance of visible lesions on transrectal ultrasound in impalpable prostate cancers: implications for staging.
Augustin H; Graefen M; Palisaar J; Blonski J; Erbersdobler A; Daghofer F; Huland H; Hammerer PG
J Clin Oncol; 2003 Aug; 21(15):2860-8. PubMed ID: 12885802
[TBL] [Abstract][Full Text] [Related]
2. Do impalpable stage T1c prostate cancers visible on ultrasound differ from those not visible?
Ohori M; Kattan MW; Utsunomiya T; Suyama K; Scardino PT; Wheeler TM
J Urol; 2003 Mar; 169(3):964-8. PubMed ID: 12576823
[TBL] [Abstract][Full Text] [Related]
3. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.
Freedland SJ; Presti JC; Terris MK; Kane CJ; Aronson WJ; Dorey F; Amling CL;
J Urol; 2003 Jun; 169(6):2129-35. PubMed ID: 12771734
[TBL] [Abstract][Full Text] [Related]
4. Transrectal ultrasound-guided transperineal 14-core systematic biopsy detects apico-anterior cancer foci of T1c prostate cancer.
Kawakami S; Kihara K; Fujii Y; Masuda H; Kobayashi T; Kageyama Y
Int J Urol; 2004 Aug; 11(8):613-8. PubMed ID: 15285751
[TBL] [Abstract][Full Text] [Related]
5. The New American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer. Clinicopathologic correlations.
Ohori M; Wheeler TM; Scardino PT
Cancer; 1994 Jul; 74(1):104-14. PubMed ID: 7516262
[TBL] [Abstract][Full Text] [Related]
6. Patients with abnormal ultrasound of the prostate but normal digital rectal examination should be classified as having clinical stage T2 tumors.
Tiguert R; Gheiler EL; Grignon DJ; Littrup PJ; Sakr W; Pontes JE; Wood DP
J Urol; 2000 May; 163(5):1486-90. PubMed ID: 10751863
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen detected prostate cancer: pathological characteristics of ultrasound visible versus ultrasound invisible tumors.
Ferguson JK; Bostwick DG; Suman V; Zincke H; Oesterling JE
Eur Urol; 1995; 27(1):8-12. PubMed ID: 7538082
[TBL] [Abstract][Full Text] [Related]
8. Localising prostate cancer: comparison of endorectal magnetic resonance (MR) imaging and 3D-MR spectroscopic imaging with transrectal ultrasound-guided biopsy.
Goris Gbenou MC; Peltier A; Addla SK; Lemort M; Bollens R; Larsimont D; Roumeguère T; Schulman CC; van Velthoven R
Urol Int; 2012; 88(1):12-7. PubMed ID: 22004874
[TBL] [Abstract][Full Text] [Related]
9. [The 1992 TNM classification of T2 prostate cancer predicts pathologic stage and prognosis better than the revised 1997 classification].
Koh H; Maru N; Muramoto M; Wheeler TM; Scardino PT; Ohori M
Nihon Hinyokika Gakkai Zasshi; 2002 Jul; 93(5):595-601. PubMed ID: 12174634
[TBL] [Abstract][Full Text] [Related]
10. Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors.
Jack GS; Cookson MS; Coffey CS; Vader V; Roberts RL; Chang SS; Smith JA; Shappell SB
J Urol; 2002 Aug; 168(2):519-24. PubMed ID: 12131301
[TBL] [Abstract][Full Text] [Related]
11. Prostate imaging may not be necessary in nonpalpable carcinoma of the prostate.
Werner-Wasik M; Whittington R; Malkowicz SB; Corn BW; Arger P; Reisinger S; Langlotz C; Alexander A; D'Amico AV; Hyslop T; Gomella L; Brownstein K; Wein AJ
Urology; 1997 Sep; 50(3):385-9. PubMed ID: 9301702
[TBL] [Abstract][Full Text] [Related]
12. Staging prostate cancer--1997: current methods and limitations.
Bostwick DG
Eur Urol; 1997; 32 Suppl 3():2-14. PubMed ID: 9267781
[TBL] [Abstract][Full Text] [Related]
13. Comparison of pathologic characteristics of T1c and non-T1c cancers detected in a population-based screening study, the European Randomized Study of Screening for Prostate Cancer.
Hoedemaeker RF; Rietbergen JB; Kranse R; van der Kwast TH; Schröder FH
World J Urol; 1997; 15(6):339-45. PubMed ID: 9436283
[TBL] [Abstract][Full Text] [Related]
14. Pathological characteristics and prognosis of nonpalpable and palpable prostate cancers with a Hybritech prostate specific antigen of 4 to 10 ng./ml.
Geary ES; Stamey TA
J Urol; 1996 Sep; 156(3):1056-8. PubMed ID: 8709306
[TBL] [Abstract][Full Text] [Related]
15. Inaccuracies in assignment of clinical stage for localized prostate cancer.
Reese AC; Sadetsky N; Carroll PR; Cooperberg MR
Cancer; 2011 Jan; 117(2):283-9. PubMed ID: 21210472
[TBL] [Abstract][Full Text] [Related]
16. Classification of localized untreated prostate cancer based on 791 men treated only with radical prostatectomy: common ground for therapeutic trials and TNM subgroups.
Stamey TA; Sözen TS; Yemoto CM; McNeal JE
J Urol; 1998 Jun; 159(6):2009-12. PubMed ID: 9598508
[TBL] [Abstract][Full Text] [Related]
17. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer.
Epstein JI; Walsh PC; Carmichael M; Brendler CB
JAMA; 1994 Feb; 271(5):368-74. PubMed ID: 7506797
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of transrectal ultrasound scan of the prostate with sector biopsies for 323 New Zealand men with suspicion of prostate cancer.
Smart R
N Z Med J; 1999 Dec; 112(1101):465-9. PubMed ID: 10678211
[TBL] [Abstract][Full Text] [Related]
19. 11C-choline positron-emission tomography/computed tomography and transrectal ultrasonography for staging localized prostate cancer.
Rinnab L; Blumstein NM; Mottaghy FM; Hautmann RE; Küfer R; Hohl K; Reske SN
BJU Int; 2007 Jun; 99(6):1421-6. PubMed ID: 17355373
[TBL] [Abstract][Full Text] [Related]
20. Transrectal ultrasound and core biopsies for the diagnosis of prostate cancer. A study of pretreatment investigation strategy for patients with suspected prostate cancer.
Norberg M
Acta Radiol Suppl; 1994; 393():1-21. PubMed ID: 8184698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
